Guardant Health Stock Price, News & Analysis

Guardant Health (Nasdaq: GH) announced a study published in Nature Medicine demonstrating the effectiveness of the Guardant360 test for guiding treatment in HER2-driven metastatic colorectal cancer. Conducted by the National Cancer Center Hospital East in Japan, the study shows that the test accurately selects patients for HER2-targeted therapy and identifies genetic alterations predicting treatment resistance. The Guardant360 test has been widely accepted, with over 150,000 tests performed and significant clinical validation through peer-reviewed publications.

Guardant Health (Nasdaq: GH) will participate in the 2021 Stifel Healthcare Conference virtually. The management is set for a fireside chat on November 15 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties can access the live and archived webcast via the company’s website. Guardant Health, a leader in precision oncology, focuses on innovative tests and analytics for cancer care, including its Guardant360 and Guardant Reveal tests.

Guardant Health (GH) reported third quarter 2021 revenue of $94.8 million, a 27% increase from the prior year. Clinical testing revenue grew 35% with 22,806 tests performed, while biopharmaceutical tests rose 58% to 4,839. The gross profit reached $64 million, with a gross margin of 67%, though operating expenses rose 34% to $171.3 million, leading to a net loss of $107.5 million. Full-year revenue guidance is projected between $360 million and $370 million.

Guardant Health (GH) has partnered with The Royal Marsden NHS Foundation Trust to establish an in-house liquid biopsy testing service, enhancing cancer diagnostics in the UK. This facility, set to operationalize by the end of 2022, will enable rapid and precise diagnostic testing for late-stage cancer patients. Guardant Health’s liquid biopsy tests are pivotal in guiding treatment decisions and facilitating clinical trials. With 375,000 new cancer cases reported in the UK from 2016-2018, this collaboration aims to improve patient outcomes through personalized treatment approaches.

Guardant Health's LUNAR-2 blood test shows promising results for colorectal cancer screening, achieving 96% sensitivity and 94% specificity in a study presented at the American College of Gastroenterology Annual Scientific Meeting.

Conducted on a cohort of 699 patients, the test particularly excels in detecting early-stage cancers, reaching 93% sensitivity for Stage 1 and 2 CRC. A larger trial, ECLIPSE, is underway to further validate these findings. Guardant aims to provide a non-invasive, easy-to-use alternative for CRC screening, potentially improving patient outcomes amidst declining screening rates.

Guardant Health (Nasdaq: GH) has appointed Myrtle Potter to its Board of Directors. This decision aims to enhance the company's mission in precision oncology.

Co-CEO Helmy Eltoukhy expressed confidence in Potter's extensive industry experience and product development expertise. Myrtle Potter, currently CEO of Sumitovant Biopharma, brings significant experience from her previous roles at Genentech and Bristol-Myers Squibb. Her appointment comes at a crucial time for Guardant Health, which focuses on innovative oncology products and aims to improve patient access to these advancements.

Guardant Health, Inc. (NASDAQ: GH) will announce its third-quarter financial results on November 4, 2021, post-market. A conference call will follow at 1:30 PM PT / 4:30 PM ET, available via webcast on the company's website. Guardant Health specializes in precision oncology, providing proprietary tests like Guardant360 and Guardant Reveal to enhance cancer care and improve patient outcomes. These tests are integral to their comprehensive oncology platform aimed at reducing healthcare costs and supporting advanced and early-stage cancer patients.

Guardant Health has launched the ORACLE study, a 1,000-patient, multi-center trial aimed at assessing the Guardant Reveal™ test's ability to predict cancer recurrence in 11 solid tumor types. The study will monitor circulating tumor DNA (ctDNA) levels for up to five years. This blood-only liquid biopsy test is designed to improve decision-making for oncologists treating early-stage cancer by identifying patients at risk for recurrence. Guardant Health intends to extend the application of this test beyond colorectal cancer, showcasing its commitment to enhancing patient care.

Guardant Health presented critical findings at the ESMO 2021 congress, revealing the need for improved HER2-directed therapies in metastatic colorectal cancer. Their Guardant360® liquid biopsy test highlighted treatment resistance patterns and molecular targets essential for personalized cancer care. Key studies emphasized the unmet need for effective treatments for HER2+ mCRC patients and provided insights into molecular features in early-onset colorectal cancer. The data underscores the importance of liquid biopsy in enhancing clinical outcomes for advanced cancer patients.